Last reviewed · How we verify
CD7 CAR T cells
CD7 CAR T cells is a CAR T-cell therapy Biologic drug developed by iCell Gene Therapeutics. It is currently in Phase 1 development.
Genetically modified T cells that express a chimeric antigen receptor targeting CD7 on malignant T cells to eliminate cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CD7 CAR T cells |
|---|---|
| Sponsor | iCell Gene Therapeutics |
| Drug class | CAR T-cell therapy |
| Modality | Biologic |
| Phase | Phase 1 |
Mechanism of action
CD7 CAR T cells are engineered to recognize and bind to CD7, a surface protein highly expressed on T-cell malignancies. Upon binding, the CAR T cells become activated and destroy the CD7-expressing cancer cells through immune-mediated cytotoxicity.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL (EARLY_PHASE1)
- A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (PHASE1, PHASE2)
- Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells (PHASE1)
- Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies (EARLY_PHASE1)
- Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies (NA)
- Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies (EARLY_PHASE1)
- A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) (PHASE2)
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD7 CAR T cells CI brief — competitive landscape report
- CD7 CAR T cells updates RSS · CI watch RSS
- iCell Gene Therapeutics portfolio CI
Frequently asked questions about CD7 CAR T cells
What is CD7 CAR T cells?
How does CD7 CAR T cells work?
Who makes CD7 CAR T cells?
What drug class is CD7 CAR T cells in?
What development phase is CD7 CAR T cells in?
Related
- Drug class: All CAR T-cell therapy drugs
- Manufacturer: iCell Gene Therapeutics — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing